Karuna Therapeutics announced the submission of a New Drug Application to the U.S. FDA for KarXT for the treatment of schizophrenia. The submission is supported by data from three positive registrational trials demonstrating consistent and robust reductions of schizophrenia symptoms.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KRTX:
- Karuna Therapeutics price target lowered to $259 from $304 at BofA
- Karuna Therapeutics initiated with an Overweight at Wells Fargo
- Karuna Therapeutics price target lowered to $258 from $274 at Mizuho
- Karuna Therapeutics names Jason Brown as CFO, Jonathan Rosin as CHRO
- Karuna Therapeutics reports Q2 EPS ($2.75), consensus ($2.78)